Radiopharmaceutical therapy and molecular imaging—together known as Theranostics—are gaining significant traction worldwide. Even though Theranostics dates back to the early 1940s, a rapid expansion ...
After a heart attack, the heart struggles to recoup and maintain energy. One-third of patients develop heart failure as a ...
Molecular response to therapy in early-stage PV patients correlates with improved event-free survival outcomes. Ropeginterferon alfa-2b significantly reduces JAK2V617F variant allele frequency, ...
4D Molecular Therapeutics trades below its cash balance, offering significant upside as its late-stage gene therapy programs advance. FDMT's lead asset, 4D-150, targets wet AMD and DME, with Phase 3 ...
Recombinant immunotoxins represent a sophisticated class of biotherapeutics that combine the targeting specificity of antibody fragments with the potent cytotoxic effects of bacterial or plant toxins.
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to ...
Cancer therapy continues to evolve, with significant advances in precision techniques such as surgery, chemotherapy, immunotherapy, radiotherapy, and ...
MP0712, a 212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in development in partnership with Orano Med Positive tumor to kidney ratio and biodistribution, ...
Highly comparable biodistribution profiles of Radio-DARPin candidates labeled with imaging isotopes 177Lu or 203Pb allows for rapid expansion of pipeline with multiple therapeutic isotopes ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
One of the persistent challenges in precision oncology is the fact that most advanced cancers are complex and highly individualized. A recent study published by Jason K. Sicklick, MD and colleagues (J ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results